Please Wait.....
Report
Europe Ocular Pain Market
Market Report I 2025-08-01 I 350 Pages I Data Bridge Market Research
The Europe ocular pain market is expected to reach USD 452,666.33 thousand by 2032 from USD 256,177.57 thousand in 2024, growing with a CAGR of 7.5% in the forecast period of 2025 to 2032.
Market Segmentation:
Europe Ocular Pain Market, By Disease Type (Ocular Pain with Eye Diseases and Ocular Pain without Primary Eye Diseases), Type (Diagnosis and Treatment), Application (Conjunctivitis, Corneal Abrasion, Blepharitis, Sty, Iritis, Sinusitis, Migraines, Glaucoma, and Others), Route of Administration (Topical, Periocular, Intraocular, Oral and Others), Drug Type (Prescription and Over the Counter), Population Type (Adults and Geriatric), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Ocular Pain Centers, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others), Country, Europe (Germany, Italy, France, U.K, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe) - Industry Trends and Forecast to 2032
Overview of the Europe Ocular Pain Market are:
Driver
- Increasing unhygienic and sedentary lifestyle
Restrain
- Side effects of eye treatment medicines
Opportunity
- Rising healthcare expenditure and disposable income
Market Players:
The key market players for Europe ocular pain market are listed below:
- Alcon Inc (Switzerland)
- Allergan (An AbbVie Company) (Ireland)
- Bausch + Lomb (U.S.)
- Kenvue (U.S.)
- Pfizer Inc (U.S.)
- Merck & Co (U.S.)
- Ocular Therapeutix Inc (U.S.)
- Sun Pharmaceutical Industries Ltd (India)
- EyePoint Pharmaceuticals Inc (U.S.)
- Fera Pharmaceuticals (U.S.)
- IACTA Pharmaceutical (U.S.)
- TheraLife Inc (U.S.)
- Opticarma India SMC Private Limited (India)
- Wellona Pharma (India)
- Oscar Remedies Pvt Ltd (India)
- Opdenas Lifesciences (India)
- Choroid Laboratories (India)
- Sylentis (Spain)
- Tarsier Pharma Ltd (Israel)
- Vyluma (U.S.)
- OKYO Pharma Limited (U.K.)
- Aldeyra Therapeutics Inc (U.S.)
- Novaliq GmbH (Germany)
- Formosapharma Pharmaceutical Inc (Taiwan)
- iVIEW Therapeutics Inc (U.S.)
TABLE OF CONTENTS
1 INTRODUCTION 59
1.1 OBJECTIVES OF THE STUDY 59
1.2 MARKET DEFINITION 59
1.3 OVERVIEW OF THE EUROPE OCULAR PAIN MARKET 59
1.4 LIMITATIONS 61
1.5 MARKETS COVERED 62
2 EUROPE OCULAR PAIN MARKET: SEGMENTATION 66
2.1 MARKETS COVERED 66
2.2 GEOGRAPHICAL SCOPE 67
2.3 YEARS CONSIDERED FOR THE STUDY 68
2.4 CURRENCY AND PRICING 68
2.5 DBMR TRIPOD DATA VALIDATION MODEL 69
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 72
2.7 MULTIVARIATE MODELLING 73
2.8 DBMR MARKET POSITION GRID 74
2.9 VENDOR SHARE ANALYSIS 75
2.10 MARKET END USER COVERAGE GRID 76
2.11 SECONDARY SOURCES 77
2.12 ASSUMPTIONS 77
3 EXECUTIVE SUMMARY 78
4 PREMIUM INSIGHTS 84
4.1 PESTAL ANALYSIS 86
4.2 PORTERS FIVE FORCES ANALYSIS 87
4.3 INNOVATION TRACKER AND STRATEGIC ANALYSIS 88
4.4 PATENT ANALYSIS- 91
4.5 SUPPLY CHAIN 94
4.6 VALUE CHAIN 97
5 TARIFF IMPACT ANALYSIS - EUROPE OCULAR PAIN MARKET 99
5.1 IMPACT ON RAW MATERIAL AND API IMPORTS 99
5.2 FINISHED PRODUCT TARIFFS AND MARKET ACCESS 99
5.3 MEDICAL DEVICE COMPONENT TARIFFS 99
5.4 TRADE AGREEMENTS AND HARMONIZATION BENEFITS 99
5.5 STRATEGIC SHIFTS AND LOCALIZATION 99
6 EUROPE OCULAR PAIN MARKET: REGULATIONS 101
7 MARKET OVERVIEW 104
7.1 DRIVERS 106
7.1.1 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE 106
7.1.2 RISING PREVALENCE OF OPHTHALMIC DISORDERS AND OCULAR PAINS 107
7.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES 108
7.1.4 GROWING CASES OF OCULAR MIGRAINE 109
7.2 RESTRAINTS 110
7.2.1 SIDE EFFECTS OF EYE TREATMENT MEDICINES 110
7.2.2 HIGH COST OF EYE TREATMENT AND MEDICATION 111
7.3 OPPORTUNITIES 112
7.3.1 RISING HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME 112
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 113
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS AND TREATMENT 114
7.4 CHALLENGES 116
7.4.1 STRINGENT RULES & REGULATIONS 116
7.4.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT 117
8 EUROPE OCULAR PAIN MARKET, BY DISEASE TYPE 119
8.1 OVERVIEW 120
8.2 OCULAR PAIN WITH EYE DISEASES 123
8.3 OCULAR PAIN WITHOUT PRIMARY EYE DISEASES 124
9 EUROPE OCULAR PAIN MARKET, BY TYPE 126
9.1 OVERVIEW 127
9.2 DIAGNOSIS 130
9.3 TREATMENT 132
10 EUROPE OCULAR PAIN MARKET, BY APPLICATION 135
10.1 OVERVIEW 136
10.2 GLAUCOMA 139
10.3 BLEPHARITIS 139
10.4 CONJUNCTIVITIS 140
10.5 CORNEAL ABRASION 140
10.6 STY 141
10.7 IRITIS 141
10.8 SINUSITIS 142
10.9 MIGRAINES 142
10.10 OTHERS 143
11 EUROPE OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 144
11.1 OVERVIEW 145
11.2 TOPICAL 148
11.3 INTRAOCULAR 149
11.4 PERIOCULAR 150
11.5 ORAL 151
11.6 OTHERS 152
12 EUROPE OCULAR PAIN MARKET, BY POPULATION TYPE 153
12.1 OVERVIEW 154
12.2 ADULT 157
12.3 GERIATRIC 157
13 EUROPE OCULAR PAIN MARKET, BY DRUG TYPE 158
13.1 OVERVIEW 159
13.2 PRESCRIPTION 162
13.3 OVER THE COUNTER 162
14 EUROPE OCULAR PAIN MARKET, BY END USER 163
14.1 OVERVIEW 164
14.2 HOSPITALS 167
14.3 SPECIALITY CLINICS 167
14.4 HOME HEALTHCARE 168
14.5 OCULAR PAIN CENTERS 168
14.6 AMBULATORY SURGICAL CENTERS 169
14.7 OTHERS 169
15 EUROPE OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL 170
15.1 OVERVIEW 171
15.2 DIRECT TENDER 174
15.3 HOSPITAL PHARMACY 174
15.4 RETAIL PHARMACY 175
15.5 ONLINE PHARMACY 175
15.6 OTHERS 176
16 EUROPE OCULAR PAIN MARKET, BY REGION 177
16.1 EUROPE 180
16.1.1 GERMANY 189
16.1.2 ITALY 197
16.1.3 FRANCE 204
16.1.4 U.K. 212
16.1.5 SPAIN 219
16.1.6 NETHERLANDS 226
16.1.7 RUSSIA 234
16.1.8 SWITZERLAND 242
16.1.9 TURKEY 250
16.1.10 AUSTRIA 258
16.1.11 NORWAY 266
16.1.12 HUNGARY 274
16.1.13 LITHUANIA 282
16.1.14 IRELAND 290
16.1.15 POLAND 298
16.1.16 REST OF EUROPE 306
17 EUROPE OCULAR PAIN MARKET: COMPANY LANDSCAPE 307
17.1 COMPANY SHARE ANALYSIS: EUROPE 307
18 SWOT ANALYSIS 308
19 COMPANY PROFILES 309
19.1 ALCON INC 309
19.1.1 COMPANY SNAPSHOT 309
19.1.2 REVENUE ANALYSIS 309
19.1.3 COMPANY SHARE ANALYSIS 310
19.1.4 PRODUCT PORTFOLIO 310
19.1.5 RECENT DEVELOPMENTS 313
19.2 ALLERGAN (AN ABBVIE COMPANY) 314
19.2.1 COMPANY SNAPSHOT 314
19.2.2 REVENUE ANALYSIS 314
19.2.3 COMPANY SHARE ANALYSIS 315
19.2.4 PRODUCT PORTFOLIO 315
19.2.5 RECENT DEVELOPMENTS 316
19.3 BAUSCH + LOMB 317
19.3.1 COMPANY SNAPSHOT 317
19.3.2 REVENUE ANALYSIS 317
19.3.3 COMPANY SHARE ANALYSIS 318
19.3.4 PRODUCT PORTFOLIO 318
19.3.5 RECENT DEVELOPMENTS 319
19.4 KENVUE 320
19.4.1 COMPANY SNAPSHOT 320
19.4.2 REVENUE ANALYSIS 320
19.4.3 COMPANY SHARE ANALYSIS 321
19.4.4 PRODUCT PORTFOLIO 321
19.4.5 RECENT DEVELOPMENT 321
19.5 PFIZER INC. 322
19.5.1 COMPANY SNAPSHOT 322
19.5.2 REVENUE ANALYSIS 323
19.5.3 COMPANY SHARE ANALYSIS 323
19.5.4 PRODUCT PORTFOLIO 324
19.5.5 RECENT DEVELOPMENT 324
19.6 ALDEYRA THERAPEUTICS, INC 325
19.6.1 COMPANY SNAPSHOT 325
19.6.2 REVENUE ANALYSIS 325
19.6.3 PRODUCT PORTFOLIO 325
19.6.4 RECENT DEVELOPMENT/NEWS 326
19.7 CHOROID LABORATORIES 328
19.7.1 COMPANY SNAPSHOT 328
19.7.2 PRODUCT PORTFOLIO 328
19.7.3 RECENT DEVELOPMENT 329
19.8 EYEPOINT PHARMACEUTICALS, INC. 330
19.8.1 COMPANY SNAPSHOT 330
19.8.2 REVENUE ANALYSIS 330
19.8.3 PRODUCT PORTFOLIO 331
19.8.4 RECENT DEVELOPMENTS 331
19.9 FERA PHARMACEUTICALS 332
19.9.1 COMPANY SNAPSHOT 332
19.9.2 PRODUCT PORTFOLIO 332
19.9.3 RECENT DEVELOPMENT 332
19.10 FORMOSAPHARMA PHARMACEUTICAL INC. 333
19.10.1 COMPANY SNAPSHOT 333
19.10.2 REVENUE ANALYSIS 333
19.10.3 PRODUCT PORTFOLIO 334
19.10.4 RECENT NEWS 334
19.11 IACTA PHARMACEUTICALS 335
19.11.1 COMPANY SNAPSHOT 335
19.11.2 PRODUCT PORTFOLIO 335
19.11.3 RECENT DEVELOPMENT 336
19.12 IVIEW THERAPEUTICS, INC.. 337
19.12.1 COMPANY SNAPSHOT 337
19.12.2 PRODUCT PORTFOLIO 337
19.12.3 RECENT DEVELOPMENT 338
19.13 MERCK & CO., INC., A SUBSIDIARY OF MERCK 339
19.13.1 COMPANY SNAPSHOT 339
19.13.2 REVENUE ANALYSIS 339
19.13.3 PRODUCT PORTFOLIO 340
19.13.4 RECENT DEVELOPMENTS 340
19.14 NOVALIQ GMBH 341
19.14.1 COMPANY SNAPSHOT 341
19.14.2 PRODUCT PORTFOLIO 341
19.14.3 RECENT DEVELOPMENTS 342
19.15 OCULAR THERAPEUTIX, INC. 343
19.15.1 COMPANY SNAPSHOT 343
19.15.2 REVENUE ANALYSIS 343
19.15.3 PRODUCT PORTFOLIO 344
19.15.4 RECENT DEVELOPMENTS/NEWS 344
19.16 OKYO PHARMA, LIMITED 345
19.16.1 COMPANY SNAPSHOT 345
19.16.2 1.1.4 REVENUE ANALYSIS 345
19.16.3 PRODUCT PORTFOLIO 345
19.16.4 RECENT DEVELOPMENTS/NEWS 345
19.17 OPDENAS LIFESCIENCES. 346
19.17.1 COMPANY SNAPSHOT 346
19.17.2 PRODUCT PORTFOLIO 346
19.17.3 RECENT DEVELOPMENT 346
19.18 OPTICARMA INDIA SMC PRIVATE LIMITED 347
19.18.1 COMPANY SNAPSHOT 347
19.18.2 PRODUCT PORTFOLIO 347
19.18.3 RECENT DEVELOPMENTS/NEWS 347
19.19 OSCAR REMEDIES PVT. LTD. 348
19.19.1 COMPANY SNAPSHOT 348
19.19.2 PRODUCT PORTFOLIO 348
19.19.3 RECENT DEVELOPMENTS/NEWS 348
19.20 SUN PHARMACEUTICAL INDUSTRIES LTD. 349
19.20.1 COMPANY SNAPSHOT 349
19.20.2 REVENUE ANALYSIS 349
19.20.3 PRODUCT PORTFOLIO 350
19.20.4 RECENT DEVELOPMENT 350
19.21 SYLENTIS 351
19.21.1 COMPANY SNAPSHOT 351
19.21.2 PRODUCT PORTFOLIO 351
19.21.3 RECENT DEVELOPMENT 352
19.22 TARSIER PHARMA LTD. 353
19.22.1 COMPANY SNAPSHOT 353
19.22.2 PRODUCT PORTFOLIO 353
19.22.3 RECENT DEVELOPMENT 354
19.23 THERALIFE, INC. 355
19.23.1 COMPANY SNAPSHOT 355
19.23.2 PRODUCT PORTFOLIO 355
19.23.3 RECENT DEVELOPMENT 356
19.24 VYLUMA 357
19.24.1 COMPANY SNAPSHOT 357
19.24.2 PIPELINE PORTFOLIO 357
19.24.3 RECENT DEVELOPMENT 358
19.25 WELLONA PHARMA 359
19.25.1 COMPANY SNAPSHOT 359
19.25.2 PRODUCT PORTFOLIO 359
19.25.3 RECENT DEVELOPMENTS/NEWS 359
20 QUESTIONNAIRE 360
21 RELATED REPORTS 364
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security